Tetranuclear Ru₂Cu₂ and Ru₂Ni₂ complexes with nanomolar anticancer activity

Area of Science:

• Coordination Chemistry
• Medicinal Chemistry
• Biochemistry

Background:

• Ruthenium complexes are investigated for their therapeutic potential.
• Novel dmoPTA-ligated ruthenium-copper and ruthenium-nickel complexes were synthesized.

Purpose of the Study:

• To synthesize and characterize novel ruthenium complexes.
• To evaluate the antiproliferative activity of these complexes against human solid tumors.
• To investigate their cellular and molecular mechanisms of action.

Main Methods:

• Synthesis and characterization of ruthenium-copper and ruthenium-nickel complexes.
• Antiproliferative assays against six human solid tumor cell lines.
• Colony formation assays (SW1573 cells).
• Mechanism of action studies (HeLa cells).
• DNA binding studies (pBR322 plasmid).

Main Results:

• Two novel complexes, [{RuCp(PPh3)2-μ-dmoPTA-1κP:2κ2-N,N'-CuCl}2-μ-Cl-μ-OCH3](CF3SO3)2·(CH3OH)4 (1) and [{RuCp(PPh3)2-μ-dmoPTA-1κP:2κ2-N,N'-NiCl}2-μ-Cl-μ-OH](CF3SO3)2 (2), were successfully synthesized and characterized.
• Both complexes exhibited significant antiproliferative activity with nanomolar GI50 values against tested human solid tumors.
• Preliminary investigations into their effects on cell colony formation, cellular mechanisms, and DNA plasmid interactions were conducted.

Conclusions:

• The synthesized ruthenium complexes demonstrate promising anticancer properties.
• Further research is warranted to elucidate their precise mechanisms of action and therapeutic potential.